New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 573.96mg equivalent to amoxicillin 500 mg;  ; potassium clavulanate 148.91mg equivalent to clavulanic acid 125 mg;   - film coated tablet - 500mg/125mg - active: amoxicillin trihydrate 573.96mg equivalent to amoxicillin 500 mg   potassium clavulanate 148.91mg equivalent to clavulanic acid 125 mg   excipient: colloidal silicon dioxide dimeticone hypromellose macrogol 4000 macrogol 6000 magnesium stearate microcrystalline cellulose opadry white oy-s-7300 as an alternative source of film coat sodium starch glycolate titanium dioxide - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml; potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml - powder for oral suspension - 125 mg/5ml - active: amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; indigo carmine; iron oxide yellow; iron oxide red; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 3 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; indigo carmine; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml; potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml - powder for oral suspension - 250 mg/5ml - active: amoxicillin trihydrate 57.394 mg/ml equivalent to amoxycillin 50mg/ml potassium clavulanate 14.89 mg/ml equivalent to clavulanic acid 12.5mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - warfarin sodium, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; pregelatinised maize starch; erythrosine; sodium starch glycollate; magnesium stearate - marevan is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. marevan is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. marevan is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. marevan is indicated for use as an adjunct in the treatment of coronary occlusion.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - warfarin sodium - tablet - 3 mg - warfarin sodium 3 mg

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - warfarin sodium - tablet - 5 mg - warfarin sodium 5 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - warfarin sodium 1mg - tablet - 1 mg - active: warfarin sodium 1mg excipient: indigo carmine iron oxide red iron oxide yellow lactose monohydrate magnesium stearate maize starch pregelatinised maize starch sodium starch glycolate - coronary occlusion; deep vein thrombosis; pulmonary embolism; peripheral vascular thromboembolic states.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - warfarin sodium 3mg - tablet - 3 mg - active: warfarin sodium 3mg excipient: indigo carmine lactose monohydrate magnesium stearate maize starch pregelatinised maize starch sodium starch glycolate - coronary occlusion; deep vein thrombosis; pulmonary embolism; peripheral vascular thromboembolic states.